1-14 of 14
Alan Sandler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

Laurent Claret, Jin Y. Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, David Gandara, Jean-Charles Soria, René Bruno
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3292–3298.
https://doi.org/10.1158/1078-0432.CCR-17-3662
Published: 15 July 2018
View articletitled, A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
Open the PDF for A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

Mark A. Socinski, Jonathan Goldman, Iman El-Hariry, Marianna Koczywas, Vojo Vukovic, Leora Horn, Eugene Paschold, Ravi Salgia, Howard West, Lecia V. Sequist, Philip Bonomi, Julie Brahmer, Lin-Chi Chen, Alan Sandler, Chandra P. Belani, Timothy Webb, Harry Harper, Mark Huberman, Suresh Ramalingam, Kwok-Kin Wong, Florentina Teofilovici, Wei Guo, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3068–3077.
https://doi.org/10.1158/1078-0432.CCR-12-3381
Published: 30 May 2013
View articletitled, A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
Open the PDF for A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer

George R. Blumenschein, Jr., Karen Reckamp, G. Joe Stephenson, Timothy O'Rourke, Gregory Gladish, Jesse McGreivy, Yu-Nien Sun, Yining Ye, Mandy Parson, Alan Sandler
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 279–290.
https://doi.org/10.1158/1078-0432.CCR-09-1675
Published: 04 January 2010
View articletitled, Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer

Leora Horn, Alan Sandler
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5040–5048.
https://doi.org/10.1158/1078-0432.CCR-09-0520
Published: 12 August 2009
View articletitled, Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer
Open the PDF for Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer in another window
Journal Articles

Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group

David M. Dilts, Alan Sandler, Steven Cheng, Joshua Crites, Lori Ferranti, Amy Wu, Robert Gray, Jean MacDonald, Donna Marinucci, Robert Comis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3427–3433.
https://doi.org/10.1158/1078-0432.CCR-07-5060
Published: 02 June 2008
View articletitled, Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group
Open the PDF for Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group in another window
Journal Articles

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

Mary J. Fidler, Athanassios Argiris, Jyoti D. Patel, David H. Johnson, Alan Sandler, Victoria M. Villaflor, John Coon, IV, Lela Buckingham, Kelly Kaiser, Sanjib Basu, Philip Bonomi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (7): 2088–2094.
https://doi.org/10.1158/1078-0432.CCR-07-4013
Published: 01 April 2008
View articletitled, The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Open the PDF for The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib in another window
Journal Articles

Bevacizumab in Non–Small Cell Lung Cancer

Alan Sandler
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4613s–4616s.
https://doi.org/10.1158/1078-0432.CCR-07-0647
Published: 01 August 2007
View articletitled, Bevacizumab in Non–Small Cell Lung Cancer
Open the PDF for Bevacizumab in Non–Small Cell Lung Cancer in another window
Journal Articles

Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

Jeffrey M. Albert, Carolyn Cao, Kwang Woon Kim, Christopher D. Willey, Ling Geng, Dakai Xiao, Hong Wang, Alan Sandler, David H. Johnson, Alexander D. Colevas, Jennifer Low, Mace L. Rothenberg, Bo Lu
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (10): 3033–3042.
https://doi.org/10.1158/1078-0432.CCR-06-2872
Published: 15 May 2007
View articletitled, Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models
Open the PDF for Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models in another window
Journal Articles

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Gregory A. Otterson, Miguel A. Villalona-Calero, Sunil Sharma, Mark G. Kris, Anthony Imondi, Mirjam Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1246–1252.
https://doi.org/10.1158/1078-0432.CCR-06-1096
Published: 22 February 2007
View articletitled, Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs
Open the PDF for Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs in another window
Journal Articles

Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

Alan Sandler, Roy Herbst
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4421s–4425s.
https://doi.org/10.1158/1078-0432.CCR-06-0796
Published: 20 July 2006
View articletitled, Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Open the PDF for Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways in another window
Journal Articles

Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer

Christopher J. Sweeney, Chris H. Takimoto, Jane E. Latz, Sharyn D. Baker, Daryl J. Murry, James H. Krull, Karen Fife, Linda Battiato, Ann Cleverly, Ajai K. Chaudhary, Tuhin Chaudhuri, Alan Sandler, Alain C. Mita, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 536–542.
https://doi.org/10.1158/1078-0432.CCR-05-1834
Published: 20 January 2006
View articletitled, Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer
Open the PDF for Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer in another window
Journal Articles

Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel

Ildiko Csiki, Jason D. Morrow, Alan Sandler, Yu Shyr, John Oates, Myles K. Williams, Thao Dang, David P. Carbone, David H. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6634–6640.
https://doi.org/10.1158/1078-0432.CCR-05-0436
Published: 15 September 2005
View articletitled, Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel
Open the PDF for Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel in another window
Journal Articles

A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities

Arno J. Mundt, Srinivasan Vijayakumar, John Nemunaitis, Alan Sandler, Herbert Schwartz, Nader Hanna, Terrence Peabody, Neil Senzer, Karen Chu, Camilla S. Rasmussen, Paul D. Kessler, Henrik S. Rasmussen, Michael Warso, Donald W. Kufe, Tapas Das Gupta, Ralph R. Weichselbaum
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (17): 5747–5753.
https://doi.org/10.1158/1078-0432.CCR-04-0296
Published: 08 September 2004
View articletitled, A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities
Open the PDF for A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities in another window
Journal Articles

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

Alan Sandler, Michael Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai Chaudhary, Karen Fife, Linda Battiato, Christopher Sweeney, Christopher Jordan, Michael Burgess, Christopher A. Slapak
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3265–3272.
https://doi.org/10.1158/1078-0432.CCR-03-0644
Published: 24 May 2004
View articletitled, A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy
Open the PDF for A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy in another window